Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Test Helps Clarify Prostate Cancer Risk After Elevated PSA

By LabMedica International staff writers
Posted on 10 Sep 2026

Prostate cancer screening often begins with prostate-specific antigen (PSA) testing, but elevated results can also occur in benign conditions, creating uncertainty and sometimes leading to invasive procedures. More...

Laboratories and urology practices need better risk stratification that preserves sensitivity while helping identify patients most likely to have clinically significant disease. A newly launched blood-based test now aims to refine decision-making after an elevated PSA result and better inform the need for biopsy.

5Q Spectra (Vancouver, BC, Canada) introduced Prostate Dx, known as the Prostate Specific Biomarker (PSB) blood test, with a global debut scheduled at the Davos of Healthcare Summit in New York City on September 14, 2026. The launch caps a 15-year development effort to advance blood-based cancer diagnostics. The test is positioned for use following a raised prostate-specific antigen to deliver cancer‑specific biological information that can guide next steps in care.

Developed as a liquid biopsy, the PSB test is a blood-based molecular diagnostic intended to close the diagnostic gap between an elevated prostate-specific antigen and surgical biopsy. Reported diagnostic discrimination is an area under the curve (AUC) of 0.86, increasing to approximately 0.92 when combined with imaging and a clinical-intelligence artificial intelligence platform. At a selected high-sensitivity threshold, reported sensitivity is approximately 95% with the potential to eliminate up to 44% of unnecessary surgical biopsies.

The test is in use by urologists following an elevated prostate-specific antigen and is currently available as a Laboratory Developed Test (LDT) through Clinical Laboratory Improvement Amendments (CLIA)-certified laboratories. An expert medical panel at the Davos of Healthcare Summit will examine early detection, clinical evidence, and the role of the PSB test in contemporary urologic oncology practice. The company reports investing more than C$85 million over 15 years in the underlying science and research and development.

“An elevated PSA certainly tells us when we should look further, but it was never designed to tell us whether prostate cancer is actually there. Our ambition has been quite simple: when a PSA level raises the alarm, our easy PSB blood test provides physicians and patients with better cancer-specific biological information about what that alarm means,” said Steve de Jaray, Co-Founder, Chairman and CEO of 5Q Spectra.

“Davos of Healthcare brings extraordinary medical science and clinical leadership to a global healthcare stage. And 5Q Spectra's new 'PSB' blood test is just that; addressing a critical diagnostic gap in today's medicine — helping men and patients beyond the uncertainty of a frightening elevated 'PSA' toward precise biological information that can guide the next step in care,” said Ransel N. Potter, Founder.

Related Links
5Q Spectra


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Electrolyte Analyzer
BKE-B
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.